Similar to PDE inhibitors, sGC activators, which are also widely used in treating diseases including cardiovascular disease and urinary track disorders [51], may also potentially increase the PCa risk due to the activation of cGMP pathways. Here, SGCB is linked to cardiovascular disorder.